JCM
SMMT icon

Jacobi Capital Management’s Summit Therapeutics SMMT Stock Holding History

Jacobi Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-500
Closed -$7K – 688
2016
Q3 		$7K Buy
+500
New +$3.61K ﹤0.01% 520

Other funds holding SMMT

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jacobi Capital Management's SMMT Position: Q4 2016 in Review

Jacobi Capital Management sold out of Summit Therapeutics (SMMT) in Q4 2016, closing a stake of 500 shares — an estimated $7K sold.

Jacobi Capital Management first reported a position in SMMT in Q3 2016 and held it in 1 quarter. The position peaked at $7K in Q3 2016. 11 funds tracked by Wall St. Rank hold SMMT as of Q4 2016.

  • Jacobi Capital Management reported no remaining Summit Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Jacobi Capital Management sold 500 Summit Therapeutics shares in Q4 2016, an estimated $7K.
  • Jacobi Capital Management first reported a position in Summit Therapeutics in Q3 2016 and held it in 1 quarter.
  • Jacobi Capital Management's Summit Therapeutics position peaked at $7K in Q3 2016.
  • 11 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2016.

Based on Jacobi Capital Management's 13F filing for Q4 2016, filed 8 Feb 2017.